Dr. Luciano Rossetti on the Function of Anti-PD-L1 Treatments in Bladder Cancer
Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.
Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.
Avelumab targets PD-L1 and blocks its interaction with PD-1 and ultimately deters the tumor in paralyzing a patient’s immune response. Rossetti says that anti-PD-L1 therapies are being looked at as monotherapies, first- and second-line therapies, as well as being used in combination with other therapies.
Neoadjuvant Mitomycin C Before TURBT for NMIBC: Safety and Potential Delayed Benefit
April 30th 2025A phase 3 trial showed neoadjuvant mitomycin C before TURBT in NMIBC patients was safe. While 12-month recurrence-free survival was similar to standard care, an 18-month trend suggested a possible delayed benefit.
Read More
UGN-102 Shows Durable Response in Recurrent Low-Grade NMIBC
April 29th 2025ENVISION trial 18-month data show UGN-102 yielded a high initial complete response (79.6%) in recurrent low-grade intermediate-risk NMIBC, with 80.6% maintaining response. The gel formulation with mitomycin offers a nonsurgical chemoablation with favorable tolerability.
Read More
TAR-200 Shows High Response in BCG-Unresponsive NMIBC with CIS
April 29th 2025Phase 2b SunRISe-1 data showed TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive, high-risk NMIBC with CIS. The 12-month CR rate was 45.9%, with durable responses and manageable safety. An FDA application is under review.
Read More
